Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans by Kim, Hyungsuk et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Molecular Pain
Open Access Research
Genetic polymorphisms in monoamine neurotransmitter systems 
show only weak association with acute post-surgical pain in humans
Hyungsuk Kim1,2, Hyewon Lee1,2, Janet Rowan3, Jaime Brahim4 and 
R a y m o n dAD i o n n e * 1,2
Address: 1National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA, 2Pain and Neurosensory Mechanisms Branch, 
National Institute of Dentaland Craniofacial Research, National Institutes of Health, Bethesda, MD, USA, 3Department of Nursing, Magnuson 
Clinical Research Center, National Institutes of Health, Bethesda, MD, USA and 4Clinical Research Core, National Institute of Dental and 
CraniofacialResearch, National Institutes of Health, Bethesda, MD, USA
Email: Hyungsuk Kim - kimhy@mail.nih.gov; Hyewon Lee - leehye@mail.nih.gov; Janet Rowan - JRowan@cc.nih.gov; 
Jaime Brahim - jbrahim@dir.nidcr.nih.gov; Raymond A Dionne* - dionner@mail.nih.gov
* Corresponding author    
Abstract
Background: Candidate gene studies on the basis of biological hypotheses have been a practical
approach to identify relevant genetic variation in complex traits. Based on previous reports and the
roles in pain pathways, we have examined the effects of variations of loci in the genes of monoamine
neurotransmitter systems including metabolizing enzymes, receptors and transporters on acute
clinical pain responses in humans.
Results: Variations in the catecholamine metabolizing enzyme genes (MAOA and COMT) showed
significant associations with the maximum post-operative pain rating while the serotonin
transporter gene (SLC6A4) showed association with the onset time of post-operative pain.
Analgesic onset time after medication was significantly associated with the norepinephrine
transporter gene (SLC6A2). However, the association between COMT genetic variation and pain
sensitivity in our study differ from previous studies with small sample sizes, population stratification
and pain phenotype derived from combining different types of pain stimuli. Correcting for multiple
comparisons did not sustain these genetic associations between monoamine neurotransmitter
systems and pain sensitivity even in this large and homogeneous sample.
Conclusion: These results suggest that the previously reported associations between genetic
polymorphisms in the monoamine neurotransmitter systems and the interindividual variability in
pain responses cannot be replicated in a clinically relevant pain phenotype.
Background
Considering moderate heritability estimates [1], multiple
pain mechanisms [2] and complex networks of pain
related molecules [3], individual variance in pain sensitiv-
ity arises from a complex network of multiple gene poly-
morphisms and environmental factors. The contribution
of each gene is subtle on multiple mechanisms, making its
signal difficult to detect. Therefore, evaluating millions of
SNPs to find a few implicated in a phenotype like pain can
be challenging. It is still necessary to choose candidate
gene regions based on their biological role [4] when test-
ing multiple SNPs to minimize the risk of false findings.
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Even if a polymorphism in a coding region does not result
in an amino acid change, or if it is not in a coding
sequence, it can still affect gene function by altering the
stability, splicing or localization of the mRNA [5]. It is
suggested that non-coding RNAs constitute a critical hid-
den layer of gene regulation in complex organisms [6].
Together with serotonin and histamine, catecholamine
neurotransmitters such as dopamine, norepinephrine and
epinephrine are collectively termed as monoamine neuro-
transmitters. Catecholamines and other monoamines
operate through G protein-coupled receptors and second
messenger systems to regulate the responsiveness of a
large area of brain circuitry. They are synthesized in a
highly restricted number of nuclei in the brain stem and
basal forebrain, whose neurons project widely to targets in
cortical and subcortical regions in the brain and in the spi-
nal cord. Neural systems involved in higher brain func-
tions such as emotion and cognition are affected by
monoamine neurotransmitters. These molecules can be
catabolized enzymatically; however, the functional activ-
ity of synaptically released monoamine neurotransmitters
is primarily terminated by their reuptake into the nerve
terminal [7].
Among the genes encoding molecules involved in
monoamine neurotransmitter systems, the catechol O-
methyltransferase gene (COMT) contains a common
functional polymorphism, COMT G1947A, also known as
COMT Val158Met, which substitutes from valine to
methionine at amino acid position 158 (or 108 of S-
COMT). This genetic variation is suggested to increase
pain report and to decrease brain opioid system activation
after an experimental pain challenge involving infusion of
hypertonic saline into the masseter muscle [8]. Haplo-
types including COMT Val158Met were recently identified
and an association was suggested with experimental pain
sensitivity and a chronic pain condition [9]. It is surpris-
ing that common variations in a single SNP or gene act
dominantly on a complex behavior such as pain with
hundreds of molecules involved in the composite pheno-
type.
Despite suggestive evidence that genetic polymorphisms
in monoamine neurotransmitter related genes, including
COMT, influence pain sensitivity, their exact roles in the
perception, interpretation and behavioral expression of
pain in humans are currently unknown. Rakvag et al[10],
for example, reported that cancer patients with the COMT
Val/Val genotype needed more morphine compared to the
Met/Met genotype suggesting that the Val/Met polymor-
phism is not fully predictive of low tolerance to pain [8].
We have examined the effects of the variations in human
genes encoding molecules involved in monoamine neu-
rotransmitter systems including loci of COMT ,monoam-
ine oxidase A and B (MAOA, MAOB), norepinephrine
transporter (SLC6A2), dopamine transporter (SLC6A3),
serotonin transporter (SLC6A4) and dopamine receptor
type 2 (DRD2) on acute clinical pain responses to investi-
gate the contributions of genetic factors on pain sensitivity
in humans.
Results
The minor allelic frequencies of each SNP in COMT,
MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4 and DRD2 are
shown in Table 1. They follow Hardy-Weinberg equilib-
rium except for SNP 12 of COMT and SNPs 1,2 and 3 of
DRD2.
For clinically-induced acute pain, COMT  SNP5
(rs740603) showed significant association with maxi-
mum post-operative pain rating. Homozygous A/A
patients of SNP5 rated their maximum post-operative
pain (N = 20, mean 52.6 mm; 95% CI, 44.5 to 60.6) lower
(ANOVA, F = 3.34, df = 106, p = 0.039) than those of het-
erozygotes (N = 53, mean 62.8 mm; 95% CI, 58.4 to 67.2)
and G/G homozygotes (N = 34, mean 63.9 mm; 95% CI,
57.5 to 64.5) (Figure 1).
Since the MAOA and MAOB are in the X chromosome and
gender differences influence pain ratings [11-13], females
and males were analyzed separately to investigate the
association. Most SNPs of MAOA in females showed asso-
ciation with maximum post-operative pain ratings reflect-
ing that the linkage disequilibrium of the genetic
variations throughout the entire gene is high (see Addi-
tional file 1). Patients of homozygous G/G for MAOA
SNP1 (rs3788862) reported maximum post-operative
pain (N = 25, mean 53.5 mm; 95% CI, 48.2 to 58.5) lower
(ANOVA, F = 5.82, df = 56, p = 0.005) than heterozygous
(N = 24, 67.3 mm; 95% CI, 59.4 to 75.3) and A/A
homozygous patients (N = 8, mean 69.6 mm; 95% CI,
57.2 to 82.1) (Figure 1). Homozygous MAOA  SNP3
(rs2283724) A/A patients reported maximum post-opera-
tive pain (N = 23, mean 53.5 mm; 95% CI, 47.8 to 59.1)
lower (ANOVA, F = 5.04, df = 56, p = 0.010) than hetero-
zygous (N = 26, 66.3 mm; 95% CI, 58.8 to 73.8) and G/G
homozygous patients (N = 8, mean 69.6 mm; 95% CI,
57.2 to 82.1). Homozygous SNP4 (rs1800659) A/A
patients of MAOA reported maximum post-operative pain
(N = 25, mean 54.6 mm; 95% CI, 49.2 to 59.9) lower
(ANOVA, F = 5.11, df = 53, p = 0.009) than heterozygous
(N = 21, 69.4 mm; 95% CI, 60.5 to 78.3) and G/G
homozygous patients (N = 8, mean 66.4 mm; 95% CI,
53.9 to 78.8). Homozygous SNP6 (rs979605) G/G
patients of MAOA reported maximum post-operative pain
(N = 24, mean 53.3 mm; 95% CI, 48.0 to 58.7) lower
(ANOVA, F = 4.63, df = 51, p = 0.014) than heterozygous
(N = 20, 66.7 mm; 95% CI, 57.8 to 75.4) and A/A
homozygous patients (N = 8, mean 66.4 mm; 95% CI,Molecular Pain 2006, 2:24 http://www.molecularpain.com/content/2/1/24
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53.9 to 78.8). Homozygous SNP8 (rs2064070) T/T
patients of MAOA reported maximum post-operative pain
(N = 25, mean 53.8 mm; 95% CI, 48.6 to 58.9) lower
(ANOVA, F = 5.18, df = 55, p = 0.009) than heterozygous
(N = 23, 67.5 mm; 95% CI, 59.6 to 75.4) and A/A
homozygous patients (N = 8, mean 66.4 mm; 95% CI,
53.9 to 78.8) (Figure 1). When we analyzed the tag SNPs
(SNP1, 2, 4 and 5) of MAOA together in females; the 2
most common combinations (G_T_A_T and A_C_G_C)
represent 90.1% of the total existing 9 combinations.
Though the homozygous patients with G_T_A_T/
G_T_A_T (N = 17, 51.3 mm; 95% CI, 44.3 to 58.3) tended
to report lower maximum post-operative pain than heter-
ozygous (G_T_A_T/A_C_G_C, N = 14, 63.7 mm; 95% CI,
53.4 to 74.0) and homozygous (A_C_G_C/A_C_G_C)
patients (N = 6, 64.7 mm; 95% CI, 50.3 to 79.1), this asso-
ciation was not statistically significant (p = 0.056). No sig-
Table 1: Information of genotyped SNPs
Gene Order SNP ID Location from 
transcription site
Nucleotide variation Rarer allele frequency
COMT 1 rs5746846 -8,663 G/C 0.43
2 rs2020917 -425 C/T 0.29
3 rs933271 2,099 T/C 0.29
4 rs5993882 8,225 T/G 0.25
5 rs740603 15,869 G/A 0.43
6 rs4646312 19,029 T/C 0.40
7 rs165722 19,705 T/C 0.45
8 rs6269 20,644 A/G 0.40
9 rs4633 20,927 T/C 0.46
10 rs4818 21,899 C/G 0.41
11 rs4680 21,963 A/G 0.46
12 rs174699 25,150 T/C 0.03
13 rs165728 27,715 T/C 0.04
MAOA 1 rs3788862 1,956 A/G 0.34
2 rs909525 37,794 T/C 0.38
3 rs2283274 44,168 A/G 0.38
4 rs1800659 58,761 A/G 0.33
5 rs979606 85,734 T/C 0.33
6 rs979605 85,955 G/A 0.33
7 87,983 C/T 0.34
8 rs2064070 93,274 T/A 0.36
MAOB 1 rs2283729 63,640 C/T 0.28
2 rs3027452 83,893 C/T 0.20
3 rs1799836 113,683 G/A 0.47
SLC6A2 1 7,551 C/T 0.06
2 rs40434 8,968 A/G 0.41
3 rs36017 28,261 G/C 0.49
SLC6A3 1 rs6350 2,347 C/T 0.09
2 rs403636 7,192 G/T 0.14
3 rs40184 50,469 G/A 0.41
4 rs12516948 54,177 T/C 0.35
5 rs10064219 60,548 C/T 0.14
SLC6A4 1 rs2066713 10,852 C/T 0.38
2 22,674 G/A 0.01
3 rs140701 24,184 G/A 0.45
4 rs4325622 36,247 A/G 0.49
5 rs1979572 50,741 C/T 0.48
DRD2 1 rs12421616 8,105 G/A 0.12
2 rs4322431 12,929 A/T 0.26
3 rs4581480 21,411 A/G 0.13
4 rs4936272 26,977 G/A 0.46
5 rs4648318 32,495 A/G 0.29
6 rs11608185 51,187 G/A 0.49
7 rs2734837 59,336 A/G 0.47
8 rs6277 62,706 T/C 0.46
9 rs6279 65,092 G/C 0.28Molecular Pain 2006, 2:24 http://www.molecularpain.com/content/2/1/24
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nificant association between clinical pain and MAOA
genetic variations was found in male patients.
Homozygous SNP2 (rs40434) G/G patients of the nore-
pinephrine transporter gene (SLC6A2) reported longer
analgesic onset time (mean 20.2 mins; 95% CI, 9.7 to
30.6) after medication (ANOVA, F = 4.69, df = 93, p =
0.011) than heterozygous (9.5 mins; 95% CI, 7.8 to 11.2)
and A/A homozygous patients (mean 11.3 mins; 95% CI,
7.3 to 15.3). Homozygous SNP1 (rs2066713) T/T patients
of the serotonin transporter gene (SLC6A4) reported the
onset of post-operative pain (mean 145.7 mins; 95% CI,
124.3 to 167.0) longer (ANOVA, F = 3.85, df = 101, p =
0.025) than heterozygous (124.4 mins; 95% CI, 115.4 to
133.5) and C/C homozygous patients (mean 117.6 mins;
95% CI, 105.2 to 130.0) (Figure 2).
Discussion
It is well-known that allele frequencies of functional vari-
ants often differ substantially among groups that have dif-
ferent geographic ancestries [14]. Therefore, our results
represent the association from only European Americans
in our cohort. In order to generalize our findings, further
studies with data collected from other major ethnic popu-
lation groups are needed. The ethnicity of the subjects was
self-determined instead of using ancestry informative
markers. It is generally acceptable that use of self-identi-
fied ethnicity based on the geographic ancestry is an
appropriate surrogate [15], although less reliable than
using explicit genetic data [16]. Allelic frequencies of the
genotyped SNPs showed consistent results with NCBI
data, which suggest the generalizability of our sample to a
European American population. Among the 5 ethnic clus-
ters (sub-Saharan Africans; Europeans and Asians west of
the Himalayas; East Asians; inhabitants of New Guinea
and Melanesia; and Native Americans) based on 377
genetic markers [17], sub-Saharan Africans and East
Asians are other major ethnic groups that need to be
investigated.
The mis-sense SNP 11 (rs4680) of COMT  markedly
reduces enzyme activity to about 20–40% of wild-type
levels [18-20]. This amino acid change may regulate the
amounts of active dopamine and norepinephrine in vari-
ous parts of the brain and therefore may be associated
with mood and other mental processes which are closely
related to pain perception [21-23] as well as the patho-
physiology of neuropsychiatric disease [20,24]. However,
it did not affect clinically induced acute pain responses in
our sample. This is not consistent with previous findings
reporting higher responses of met/met homozygotes at
158 amino acid position [8]. SNP 11 met/met homozy-
Maximum post-operative pain ratings and SNPs from COMT and MAOA Figure 1
Maximum post-operative pain ratings and SNPs from COMT and MAOA. COMT: catechol O-methylatransferase gene MAOA: 
monoamine oxidase A gene, females only *, p < 0.05 **, p < 0.01Molecular Pain 2006, 2:24 http://www.molecularpain.com/content/2/1/24
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gotes at codon 158, claiming to be associated with higher
pain sensitivity, showed no significant association indi-
vidually with clinically induced acute pain responses in
our sample. An opposite trend was suggested as the met/
met subjects showed lower pain responses than val/met
and val/val subjects though it was not statistically signifi-
cant (data not shown). Other studies also failed to repli-
cate the higher pain responses in met/met homozygotes
[10,25]. This discrepancy may be explained by the small
sample size of Zubieta et al. which compared a val/val
homozygous group (n = 3) to a heterozygous group (n =
11), and the met/met homozygous group (n = 4) to a het-
erozygous subgroup (n = 9 of the 11). The authors did not
provide ethnic information of the subjects; even a small
amount of population admixture can undermine an asso-
ciation study and lead to false positive results [26]. Differ-
ences in the pain induced experimental stimuli (saline
injection into the masseter muscle) verses surgical extrac-
tion of impacted teeth and subsequent acute inflamma-
tion may also produce different phenotypes that activate
different pathways.
Inconsistency was also found in the analysis of hap-
loblocks. In contrast to previously reported lower sensory
ratings of pain in G_C_G_G haplotypes [9], our haplotype
data (not shown) demonstrated that G_C_G_G homozy-
gotes are actually included in the higher pain sensitive
populations, though the association is not very strong.
Diatchenko et al. reported association between COMT
variations and experimental pain and chronic pain condi-
tions based on a sample composed of 85% European
Americans and 15% from other ethnic populations. The
experimental pain phenotype combined pressure pain
thresholds, thermal pain thresholds and tolerance, tem-
poral summation of thermal pain, ischemic pain thresh-
old and tolerance. These different stimulus modalities
likely cause pain via different neural mechanisms. Ther-
mal and cold pain sensitivity, for example, are genetically
dissociable [11] and there are at least 5 fundamentally dif-
ferent types of nociception [27], which may be inappro-
priate to mix for genetic analyses. The association between
COMT and risk of developing temporomandibular disor-
ders in Diatchenko et al. is based on 15 TMD patients out
of 170 subjects and may be confounded by the ethnic
admixture. Analyses for the individual SNP8 (rs6269) and
SNP10 (rs4818) also did not show any significant associ-
ation in our patient sample while Diatchenko et al.
reported significant associations (p < 0.01). Thus, our fail-
ure to replicate previous studies related to COMT and pain
[8,9] may be due to the small sample sizes, population
stratification and the composite pain phenotype used in
the latter publications.
Instead of SNP 11, SNP 5 (rs740603) in intron 1 showed
moderate but significant association with maximum post-
operative pain rating. The observed relationship between
SNP5 of COMT and maximum post-operative pain rating
suggests that another mechanism including different, uni-
dentified but significant genetic factors may play a role in
acute clinical pain perception. Even if a polymorphism is
not in a coding sequence, it can still affect gene function
by altering the stability, splicing, localization of mRNA or
generating a small RNA. Emerging evidence suggests that
the non-coding portions (i.e., introns) of the protein cod-
ing gene transcripts play an important role in regulatory
pathways. Regulatory elements for gene expression in
introns [28,29] or intron-derived microRNAs [30] are
good examples. DNA sequences might be involved in the
three-dimensional positioning of chromosomes in the
nucleus enabling chromosome-chromosome interac-
tions. Any portion of genomic DNA can be meaningful for
the phenotype because of the complicated dynamics of
DNA structure and gene expression [31]. Gene expression
is generally regulated by DNA regions outside of gene
regions that actually encode proteins, and there is much
that is not yet understood about this process [32]. The
information in the genome sequence must be considered
in the large context of the chromosome [33] as well as in
relationship with encoding proteins.
MAO, another catabolizing enzyme of monoamine neu-
rotransmitters, is present in two isoforms (MAO A and
MAO B), which share 70% amino acid sequence identity.
These two forms differ with regard to several biochemical
properties including their substrate specificity, cellular
localization and regulation by pharmacologic agents.
They are encoded by two closely linked genes with 15
exons on the X chromosome organized in opposite direc-
tions, tail to tail, 24 kb apart. However, MAO A and MAO
B genes (MAOA and MAOB) have different tissue specific
Time dependant pain responses and monoamine neurotrans- mitter transporter SNPs Figure 2
Time dependant pain responses and monoamine neurotrans-
mitter transporter SNPs. C6A2: norepinephrine transporter 
gene SLC6A4: serotonin transporter gene *, p < 0.05Molecular Pain 2006, 2:24 http://www.molecularpain.com/content/2/1/24
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expression and functions which may be caused by differ-
ences in gene regulation including TATA box and Sp1 site
[34]. While compulsive/aggressive behavior was observed
in MAOA knockout mice [35], MAO activity has not been
investigated for its possible association with pain pheno-
types. The association studies between genetic polymor-
phisms of MAOA,  MAOB  and other human behaviors
show inconsistent results [36-38].
We analyzed females and males separately for MAOA and
MAOB because they are located on the X chromosome.
Generally, males tend to report pain stimuli lower than
females and they only have one allele of homozygotes.
Therefore, heterozygous patients who can only be
females, may show false higher pain ratings than homozy-
gotes who are mixed females and males. It is not surpris-
ing that most SNPs from MAOA  showed similar
significant associations in females because all SNPs in the
MAOA  region show high linkage disequilibrium with
each other (see Additional file 1). Common combina-
tions of tag SNPs of MAOA were analyzed with the maxi-
mum post-operative pain ratings and showed similar
tendency with the individual SNPs, as expected. However,
this association is non-significant, even without the mul-
tiple testing corrections. Though MAOA and MAOB are
closely located on the X chromosome, they have many dif-
ferent characteristics including the expression sites and
substrates. In pain sensitivity, they also have different
effects as MAOB SNPs do not show any significant associ-
ation.
Since the re-uptake of monoamine neurotransmitters
through specific transporters is the major method of elim-
ination from the neural synapse, it is not surprising that
the genetic variations in norepinephrine transporter gene
(SLC6A2) and the serotonin transporter gene (SLC6A4)
affect monoamine neurotransmitter mediated human
behaviors including responses to painful stimuli. Unlike
catabolizing enzyme encoding genes such as COMT and
MAO, SNPs of transporter genes showed association with
time dependant pain responses though it is not clear how
these genetic variations influence pain or analgesic onset.
Given the significant findings between genetic variations
of monoamine neurotransmitter systems and sensitivity
to clinical pain, additional high density genotyping of
these genes regions may be informative. More than 30
SNPs with heterozygosity greater than 0.25 are reported
and 6 nonsynonymous SNPs exist in COMT alone. Some
of these SNPs induce nonsynonymous amino acid change
though their heterozygosity is low or not known. Future
studies including higher density genotyping around the
candidate regions are needed.
Among the dopaminergic receptors, D2 receptor (DRD2)
appears to be the major autoreceptor for dopaminergic
neurons [39]. It was reported that DRD2 influences base-
line nociception in the mouse, although this effect is weak
and submodality selective. DRD2 receptors may contrib-
ute to attenuation of referred hypersensitivity caused by
sustained nociception [40]. Despite the important role of
DRD2 in the dopamine system, no significant association
between genetic variations in DRD2  and clinically
induced pain was found in our sample. Due to compli-
cated interactions not only within monoamine neuro-
transmitter systems but also with related other enzymes
and other pain modulating systems, it is not clear whether
genetic polymorphisms in DRD2 affect pain sensitivity.
Many association studies for common diseases suggest
that many different genes distributed throughout the
human genome contribute to the total genetic variability
of a particular complex trait, with any single gene account-
ing for no more than a few percent of the overall variabil-
ity of the trait [41].
Even though we found some significant association
between genetic variations of monoamine neurotransmit-
ter system and clinical pain sensitivity, for modest genetic
effects and for identification of genotypic subgroups,
much larger sample sizes are required. The SNPs showing
association with pain sensitivity are in introns or untrans-
lated regions. More complicated unidentified mechanism
rather than the simple amino acid change of coding
sequence may play a major role. Regardless of the signifi-
cant associations, the risk of chance finding should be
considered carefully. When we performed correction of
the multiple testing with Bonferroni's correction, all of
our significant associations were statistically non-signifi-
cant. It should be emphasized that our data set is larger
and more homogeneous than the studies reporting posi-
tive findings of COMT and pain [8,9]. Therefore, it is pos-
sible that the reported genetic associations between
monoamine neurotransmitter system including metabo-
lizing enzymes and transporters and pain are not justified
by the available evidence.
A sample drawn from only one gender group may increase
the ability to study phenotype-genotype association. It is
reported that a gender difference exists in the genetic var-
iation effect on pain responses [12,13,22,42,43]. How-
ever, it is still debatable that the independent analysis of
each gender is necessary. It was reported that there is no
evidence for a sex-specific genetic influence in the liability
of heritability of clinical neck pain, especially in the clini-
cal condition [44]. Analyzing females and males together
in our study can be meaningful because overwhelming
clinical pain and allelic frequencies are not different
between genders as well as it enables us to compare the
results of COMT with previously studies of Zubieta et al
and Diatchenko et al. It is also necessary to take account
of substructure of examined population even in a rela-Molecular Pain 2006, 2:24 http://www.molecularpain.com/content/2/1/24
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tively homogenous genetic group such as the Icelanders.
Even Icelanders cannot be considered to be a single, ran-
domly interbreeding population [45]. This will probably
be more important in larger populations like European
Americans or African Americans. Descriptors such as eth-
nicity capture only some of the ancestral information
about the biological and environmental factors that influ-
ence phenotypic characteristics [16]. Other potential
interacting factors such as psychological profiles should
also be considered in the future studies.
Conclusion
Our results suggest that genetic polymorphisms in the
monoamine neurotransmitter systems including COMT,
MAOA,  SLC6A2  and  SLC6A4  may contribute but very
weakly, if any, to the interindividual variability in pain
responses to clinically induced acute injury. These results
suggest that the previously reported associations between
genetic polymorphisms in the monoamine neurotrans-
mitter systems and the interindividual variability in pain
responses cannot be replicated in a clinically relevant pain
phenotype.
Methods
Subjects
The study was approved by the Institutional Review Board
of the National Institute of Dental and Craniofacial
Research and informed consent was obtained from all
subjects. Among 221 patients undergoing oral surgery,
European Americans (60 females and 52 males), age
ranged from 17 to 35 years, were analyzed in this study.
Patients underwent standardized surgery by the same oral
surgeon removing third molar teeth that included at least
one bony impacted mandibular third molar. After receiv-
ing pre-medication with intravenous midazolam (4.9 ±
0.2 mg) and local anesthesia with 2% lidocaine (250.6 ±
43.0 mg) with epinephrine 1:100,000, a mucoperiosteal
flap was raised and retracted, bone removed, and the teeth
were sectioned as needed to facilitate extraction of the
impacted lower third molars.
SNP genotyping
For genotyping, 50 ml of venous blood from each subject
was collected. DNA isolation was performed with the
Puregene™ DNA isolation kit (Gentra Systems Inc., Min-
neapolis, Minnesota, USA) following manufacturer's
instructions.
For SNP genotyping, Assays-on-Demand or Assays-by-
Design SNP Genotyping Products (Applied Biosystems,
Foster City, California, USA) were used. Each well con-
tained 2.5 μl of Taqman universal master mix, 0.25 μl of
genotyping assay mix and 2.25 μl of DNAse free water.
Polymerase chain reaction (PCR) was performed under
the following conditions: 95 °C, 10 min followed by 40
cycles of 92 °C, 15 seconds and 60 °C, 1 minute in a Per-
kin-Elmer™ 9700 thermocycler (Perkin-Elmer Inc., Bos-
ton, Massachusetts, USA). Following PCR, fluorescence of
each well was measured using the ABI Prism 7900
Sequence Detection System (Applied Biosystems, Foster
City, California, USA). From the genomic sequences
including their flanking regions, 46 SNPs from COMT,
MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4 and  DRD2
were genotyped. Detailed information of genotyped SNPs
is in Figure 1 and Table 1.
Genotype discrimination was performed using Taqman
Sequence Detector version 2.1 software. Samples that
failed to amplify were not included in the final analysis.
Clinical pain measurement
Clinically induced pain was recorded with a paper and
pencil form of a 100 mm visual analogue scale (VAS).
After the extraction of the impacted third molars, pain was
recorded every 20 minutes by VAS until subjects requested
analgesic medication as the local anesthesia was elimi-
nated and post-operative pain onset occurred. Ketorolac
tromethamine (Toradol) was administered intravenously
at the recommended dose (30 mg) and pain was recorded
by VAS again at 15 minutes interval for 180 minutes. The
maximum post-operative pain rating, onset time of post-
operative pain, and the analgesic onset time after medica-
tion were used as measures of clinical pain.
Data analysis
Analysis of variance (ANOVA) with Duncan's post hoc
analysis was used to examine the effects of individual
SNPs on pain response. A probability of < 0.05 was con-
sidered to be significant for statistical comparison. The
total number of statistical comparisons evaluating the
association between genetic variation and pain responses
in this study was 138.
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